The 7 analysts offering 12-month price forecasts for Orchard Therapeutics PLC have a median target of 15.00, with a high estimate of 26.00 and a low estimate of 13.00. The median estimate represents a +212.50% increase from the last price of 4.80.
The current consensus among 7 polled investment analysts is to Buy stock in Orchard Therapeutics PLC. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.45
Reporting Date Nov 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.